Research Use Only — Not for Human Consumption. Every compound discussed in this article is supplied strictly as a laboratory research material. These materials are not medicines, dietary supplements, or food products, and nothing in this article constitutes medical advice or supports any human or veterinary application.

BPC-157 is a synthetic pentadecapeptide widely referenced in laboratory peptide research. First described in the gastrointestinal research literature during the 1990s, this 15-residue sequence has since become a standard subject in studies of peptide stability, cell migration assays, and analytical method development. This article provides a laboratory-focused overview of BPC-157’s molecular structure, the handling properties relevant to researchers, its principal in vitro study applications, and the analytical techniques used to verify its identity and purity.

Molecular Structure and Physicochemical Properties

BPC-157 is a linear peptide composed of fifteen amino acid residues with the single-letter sequence GEPPPGKPADDAGLV — glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine, and valine. Its molecular weight is approximately 1419.5 daltons. The sequence contains no cysteine residues and therefore forms no disulfide bonds, and it carries no post-translational modifications such as glycosylation or amidation in its standard synthetic form.

The sequence is notable for its high proline content — four of the fifteen residues are proline — which constrains the peptide backbone and influences its conformational behavior in solution. The N-terminal region (GEPPP) is relatively hydrophobic and rigid, while the central and C-terminal regions include charged residues (glutamic acid, lysine, two aspartic acids) that confer aqueous solubility under typical laboratory buffer conditions. This balance of hydrophobic and hydrophilic character is one reason the peptide is frequently selected as a model compound when laboratories develop or validate reversed-phase chromatography methods.

The abbreviation "BPC" derives from "body protection compound," the name given to the protective protein fraction isolated from mammalian gastric juice from which the pentadecapeptide sequence was originally identified and then produced by laboratory synthesis (Sikiric et al., 2011). In the research-supply context, BPC-157 is manufactured by solid-phase peptide synthesis (SPPS) and purified by preparative HPLC, with identity confirmed by mass spectrometry — the same manufacturing and quality-control paradigm applied to most synthetic research peptides.

Stability Profile and Laboratory Handling Considerations

One of the most frequently discussed characteristics of BPC-157 in the literature is its reported stability across a range of pH conditions, including acidic environments that degrade many comparable peptides. This property was characterized in early gastric research and is often cited when the peptide is used as a reference material in forced-degradation or stability-indicating method studies. For the laboratory scientist, the practical implication is straightforward: BPC-157 is a comparatively forgiving analyte during sample preparation, though standard peptide-handling discipline still applies.

As with all synthetic peptides, lyophilized BPC-157 should be stored desiccated at -20 °C or below, protected from light and moisture. Working solutions should be prepared in clean, low-binding vessels, and repeated freeze–thaw cycles of stock solutions should be avoided in favor of single-use aliquots. Adsorption to container surfaces — a common source of variability in dilute peptide solutions — can be minimized by using siliconized or low-protein-binding plastics and by verifying recovery during method validation.

In Vitro Study Applications

In the published literature, BPC-157 appears most often in cell-based laboratory models. The principal in vitro applications include:

• Cell migration (scratch wound) assays. Monolayers of fibroblasts or epithelial cells are mechanically wounded and the rate of gap closure is measured by time-lapse microscopy. BPC-157 is frequently included in such assay panels as a comparator peptide when laboratories evaluate migration responses.
• Fibroblast proliferation assays. Tendon- and ligament-derived fibroblast cultures have been used to study proliferative and migratory responses to peptide exposure, with readouts such as MTT/XTT viability assays, BrdU incorporation, or direct cell counting (Seiwerth et al., 2018).
• Endothelial cell models. In vitro tube-formation assays on basement-membrane matrices and endothelial migration assays are standard tools in angiogenesis-related research, and BPC-157 has been referenced in the literature alongside classical angiogenic growth factors in these systems.
• Gene and protein expression profiling. Quantitative PCR and Western blotting of growth-factor and extracellular-matrix markers in treated cell cultures are commonly used to characterize cellular responses at the molecular level.

It is important to emphasize what these models are: controlled laboratory systems for studying cellular behavior. Results from in vitro assays describe how cells behave in culture dishes under defined conditions; they do not establish safety or efficacy in any living organism and must never be presented as such.

Analytical Methods for Identity and Purity Verification

A credible research-peptide program verifies every lot of BPC-157 with orthogonal analytical methods before the material is used in experiments. The standard workflow includes:

• Reversed-phase HPLC (RP-HPLC) with UV detection, typically on a C18 column with a water/acetonitrile gradient containing trifluoroacetic acid. Purity is assessed by peak-area normalization, and the method must be stability-indicating — capable of resolving the intact peptide from deletion sequences, oxidation products, and other synthesis-related impurities.
• Mass spectrometry (LC-MS or MALDI-TOF) to confirm the molecular ion at the expected m/z and to verify the amino acid sequence through tandem MS (MS/MS) fragmentation when required.
• Amino acid analysis (AAA) following acid hydrolysis, which provides an independent check of composition and supports net peptide content determination.
• Karl Fischer titration or thermogravimetric analysis for residual moisture and counterion/salt content, both of which affect the calculated net peptide content of a lyophilized powder.

A complete certificate of analysis (COA) for a BPC-157 lot should therefore report the HPLC chromatogram and purity, the mass spectrum with the observed molecular weight, the net peptide content, moisture content, and storage conditions. Laboratories should archive these documents as part of their analytical records to support traceability and data integrity.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
2. Seiwerth S, Milavic M, Vukojevic J, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989.
3. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft-tissue healing. Cell Tissue Res. 2019;377(2):153-159.
4. Sikiric P, Rucman R, Turkovic I, et al. Brain-gut axis and pentadecapeptide BPC157: theoretical, experimental and clinical implications. Curr Neuropharmacol. 2016;14(8):857-865.

This article is intended for qualified laboratory researchers only. The materials described are research chemicals not intended for human or veterinary use, and no statement in this article should be interpreted as a medical, therapeutic, or dosing recommendation.